Results 21 to 30 of about 85,247 (140)
Viruses, 2022 New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to emerge, causing surges, breakthrough infections, and devastating losses—underscoring the importance of identifying SARS-CoV-2 antivirals.
Ching-Wen Chang +8 more
doaj +1 more source
Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
Antibiotics, 2021 Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths.
Ching-Chi Lee +2 more
doaj +1 more source
Viruses, 2022 Feline infectious peritonitis (FIP) is a fatal disease of cats that currently lacks licensed and affordable vaccines or antiviral therapeutics. The disease has a spectrum of clinical presentations including an effusive (“wet”) form and non-effusive (“dry”
Sarah Cook +10 more
doaj +1 more source
The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review
Saudi Pharmaceutical Journal, 2022 Background: Throughout the time of the global pandemic of SARS-CoV-2 virus, there has been a compelling necessity for the development of effective antiviral agents and prophylactic vaccines to limit the virus spread, disease burden, hospitalization, and ...
Lina Kamal +4 more
doaj +1 more source
Journal of Veterinary Internal Medicine, Volume 37, Issue 5, Page 1772-1783, September/October 2023., 2023 Abstract Background Nucleoside analog GS‐441524 is effective in treating cats with feline infectious peritonitis (FIP). Investigation into the use of parent nucleotide analog remdesivir (GS‐5734) is needed. Objectives To assess efficacy and tolerability of remdesivir with or without transition to GS‐441524 in cats with FIP and document clinical and ...
Sally J. Coggins +6 more
wiley +1 more source
Fundamental &Clinical Pharmacology, Volume 37, Issue 4, Page 726-738, August 2023., 2023 Abstract The COVID‐19 pandemic remains a major health concern worldwide, and SARS‐CoV‐2 is continuously evolving. There is an urgent need to identify new antiviral drugs and develop novel therapeutic strategies. Combined use of newly authorized COVID‐19 medicines including molnupiravir, nirmatrelvir, and remdesivir has been actively pursued ...
Daisy Yan, Bingfang Yan
wiley +1 more source
Perspectives for antivirals to limit SARS-CoV-2 infection (COVID-19) [PDF]
Microbiology Australia, 2021 Compared with vaccines, antivirals for curbing COVID-19 (SARS-CoV-2 infection) have been developed at a much lower pace. Favipiravir has proven efficacious (in hamsters) but only at a very high dose which may not be feasible in humans.
Erik De Clercq
doaj
Repurposing clinically available drugs and therapies for pathogenic targets to combat SARS‐CoV‐2
MedComm, Volume 4, Issue 3, June 2023., 2023 In this review, authors provide a comprehensive overview of various identified pathogenic targets and pathways, as well as corresponding repurposed approved/clinical drugs and their potential against COVID‐19. Moreover, authors summarizenumerous potential pathogenic targets associated with viral life cycle and virus–host cell communication, repurposed ...
Yiying Xue +6 more
wiley +1 more source
Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
MedComm, Volume 3, Issue 3, September 2022., 2022 In this article, we described the discovery of the Omicron variant, biological characteristics of the Omicron variant, immune escape, mutations, patients’ clinical features, vaccination, detection methods, treatment with drugs and neutralizing antibodies, and protective measures taken.
Ailan Xu +10 more
wiley +1 more source
Pharmacology Research &Perspectives, Volume 10, Issue 2, April 2022., 2022 Abstract GS‐441524, the parent nucleoside of remdesivir, has been proposed to be effective against Covid‐19 based on in vitro studies and studies in animals. However, randomized clinical trials of the agent to treat Covid‐19 have not been conducted.
Henrik Berg Rasmussen +2 more
wiley +1 more source